Skip to main content

Table 4 Potential VTE risk factors and risk estimates for VTE (definite and probable) based on 4320 women. Comparative assessment with logistic regression analysis: Odds ratio (OR) and 95% confidence interval (95% CI)

From: Comparison of incidence/risk of venous thromboembolism (VTE) among selected clinical and hereditary risk markers: A community-based cohort study

 

Non-cases

Cases

Crude OR (95% CI)

Adjusted* OR (95% CI)

 

Non-exposed

Exposed

Non-exposed

Exposed

  

Demographic data

      

Age: 30+ years vs. <30

2830

1456

13

21

3.1 (1.6–6.3)

2.4 (1.1–5.3)

BMI: 25+ vs. <25

3199

1076

19

15

2.3 (1.2–4.6)

2.0 (0.9–4.1)

OC use: ever vs never

344

3941

2

32

1.4 (0.3–5.9)

1.3 (0.3–5.8)

Other hormones: ever vs. never

4000

267

31

3

1.4 (0.4–4.8)

0.86 (0.2–2.9)

Smoking: ever vs. never

2006

2278

16

18

1.0 (0.5–1.9)

0.8 (0.4–1.7)

Medical history

      

Personal history of VTE: yes vs. no

4249

37

30

4

15.3 (5.1–45.9)

6.6 (1.8–24.6)

Family history of VTE: yes vs. no

3816

470

24

10

3.4 (1.6–7.1)

2.4 (1.0–5.4)

Family history of varicous veins: yes vs. no

2384

1902

11

23

2.6 (1.3–5.4)

1.9 (0.8–4.1)

Family history of MI: yes vs. no

3804

482

26

8

2.4 (1.1–5.4)

2.0 (0.8–4.6)

Family history of stroke: yes vs. no

3984

302

29

5

2.3 (0.9–5.9)

1.2 (0.4–3.5)

Laboratory & genetic markers

      

FVL mutation§: yes

4006

267

29

4

2.1 (0.7–5.9)

2.0 (0.7–6.0)

Prothrombin mutation§: yes

4059

140

29

2

2.0 (0.5–8.5)

2.3 (0.5–10.0)

Protein C deficiency#: yes

4087

194

30

4

2.8 (0.98–8.0)

3.0 (0.9–10.4)

AT deficiency#:yes

4073

209

33

1

0.6 (0.1–4.3)

0.5 (0.1–3.5)

MTHFR§: yes

1784

2415

14

17

0.9 (0.4–1.8)

0.95 (0.5–1.97)

  1. § homo- and heterozygote together
  2. # definition see methods
  3. * adjusted for all other variables